Ratings Moves: AIR,...
Health Care: Drugs
Valeant Pharmaceuticals International Inc (VRX: NYSE)
$78.17 2.42 | 3.19%
05/17/13 - 04:05 PM ET
1.43M / 1.41M
Vol / Avg. Vol:75.43 / 75.75
Open / Prev. Close:74.72 - 78.37
Today's Range:42.47 - 78.37
52 Wk Range:30.73%
Performance YTD:TheStreet Rating:
Portfolios with VRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ProRuane Cunniff
- ContributorStocks With Big Insider Buy...
- UserRetirement stocks
- ProPrivate Capital Management
- ProViking Global Investors
- UserWatch
- ContributorStocks With Big Insider Buy...
- Contributor12 Top Health Care Picks fo...
- ContributorStocks With Big Insider Buy...
Latest VRX Headlines from TheStreet
- Valeant Pharmaceuticals International Stock Hits New 52-Week High (VRX) 05.14.13 | 10:05 am
- Valeant Pharmaceuticals International Inc (VRX): Today's Featured Health Care Laggard 05.09.13 | 05:05 pm
- Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Laggard 05.01.13 | 05:05 pm
- 3 Health Care Stocks Rising on Big Volume 04.29.13 | 03:04 pm
- Valeant Pharmaceuticals International Rises On Unusually High Volume (VRX) 04.29.13 | 01:04 pm
- 5 Drugs Stocks Nudging The Industry Higher 04.29.13 | 01:04 pm
- Stock Futures Fueled by Anticipated Stimulus 04.29.13 | 07:04 am
- Valeant Pharmaceuticals International Inc (VRX): Today's Featured Health Care Laggard 04.22.13 | 05:04 pm
- 4 Stocks Pushing The Drugs Industry Downward 04.22.13 | 01:04 pm
- 5 Stocks Pulling The Drugs Industry Downward 04.12.13 | 01:04 pm
Press Releases for VRX
- Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013 - PR Newswire 04.16.13 | 08:04 am
- Actavis Reaches Agreements With Valeant To Launch Generic Versions Of Ziana® And Zyclara® - PR Newswire 04.10.13 | 08:04 am
- Actavis Reaches Agreements With Valeant To Launch Generic Versions Of Ziana® And Zyclara® - PR Newswire 04.10.13 | 08:04 am
- Merz Pharma Group Withdraws Proposal To Acquire Obagi Medical Products - PR Newswire 04.08.13 | 07:04 am
- Actavis And Valeant Announce Actavis As Exclusive Authorized Generic Marketer Of Zovirax® Ointment; Co-Promotion Agreements On Zovirax® Cream And Cordran® Tape - PR Newswire 04.05.13 | 08:04 am
- Actavis And Valeant Announce Actavis As Exclusive Authorized Generic Marketer Of Zovirax® Ointment; Co-Promotion Agreements On Zovirax® Cream And Cordran® Tape - PR Newswire 04.05.13 | 08:04 am
- Valeant Pharmaceuticals Provides Update To Recent Event - PR Newswire 04.04.13 | 08:04 am
- Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash - PR Newswire 04.03.13 | 08:04 am
- Valeant Pharmaceuticals Announces Private Exchange Offer - PR Newswire 03.29.13 | 05:03 pm
- Rigrodsky & Long, P.A. Announces Investigation Of Obagi Medical Products, Inc. Buyout - PR Newswire 03.27.13 | 01:03 pm
Partner Headlines for VRX
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- IBD Big Cap 20 Analysis: Some Stocks Show Resilience - Investor's Business Daily 04.08.13 | 06:04 pm
- How The IBD 50 Can Help Investors Find Winning Stocks - Investor's Business Daily 04.05.13 | 04:04 pm
- AbbVie Offers Nice Dividend Yield, Stock At New High - Investor's Business Daily 04.01.13 | 05:04 pm
- Stocks Fall On Weak Data; Sinclair Broadcast Off High - Investor's Business Daily 04.01.13 | 01:04 pm
- Stocks Pop, But Declining Volume Dims Day's Gains - Investor's Business Daily 03.20.13 | 05:03 pm
- Stock Averages Move Up But Volume Can't Keep Pace - Investor's Business Daily 03.20.13 | 04:03 pm
- Stocks Up Ahead Of Fed Statement; Lennar At New High - Investor's Business Daily 03.20.13 | 01:03 pm
- Stocks Hold Up, Trade Mixed; Valeant, Obagi Lifted - Investor's Business Daily 03.20.13 | 12:03 pm
- Stocks End Mixed As Cyprus Rattles Investors; Ocwen dives - Investor's Business Daily 03.19.13 | 04:03 pm
